Company newsCompany release
Blackstone BX
Blackstone to provide $750 million to Johnson & Johnson for drug development
The funds support Phase 3 clinical development of OLN324, an investigational therapy for serious retinal vascular diseases.
GetSignal
Blackstone said funds managed by Blackstone Life Sciences will provide $750 million in development funding to Johnson & Johnson, announced November 16, 2026.
Key facts
- Amount
- $750 million
- Recipient
- Johnson & Johnson
- Program
- OLN324, Phase 3 clinical development
- Announced
- November 16, 2026
Source: The company's release on Business Wire, November 16, 2026.
Written by GetSignal with AI from the company's press release. How we make news
Not investment advice.
More company news
Blackstone first, then the newest- Blackstone completes $1.1 billion senior notes offering
BX · Blackstone · Form 8-K · Nov 2, 2026
- Blackstone funds agree to invest $3.1 billion in Mitsubishi Corporation unit
BX · Blackstone · Company release · Nov 2, 2026
- Blackstone subsidiary prices $1.1 billion senior notes offering
BX · Blackstone · Form 8-K and release · Oct 27, 2026
- S&P Global starts senior notes offering, subject to market conditions
SPGI · S&P Global · Company release · Nov 16, 2026
- AMD completes acquisition of World Labs
AMD · Advanced Micro Devices · Company release · Nov 16, 2026
